Table 1 Baseline characteristics and frequency of eight targetable genomic alterations of 3115 NSCLC patients from the DFCI cohort according to tumor histology

Age at diagnosis

Median

66

68

58.5

64

67

65.5

66

Sex

Male (%)

883 (36.9%)

204 (60.5%)

16 (22%)

10 (42%)

8 (53%)

135 (50%)

1256 (40.4%)

Female (%)

1512 (63.1%)

133 (39.5%)

58 (79%)

14 (58%)

7 (47%)

135 (50%)

1859 (59.6%)

Site

Primary (%)

1400 (58.5%)

244 (72.4%)

62 (84%)

13 (54%)

14 (93%)

133 (49.3%)

1866 (59.9%)

Metastasis (%)

910 (38.0%)

77 (22.8%)

11 (15%)

11 (46%)

1 (7%)

111 (41.1%)

1121 (36.0%)

Local Recurrence (%)

36 (1.5%)

9 (2.7%)

0 (0%)

0 (0%)

0 (0%)

5 (1.9%)

48 (1.5%)

Unspecified (%)

49 (2.0%)

7 (2.1%)

1 (1%)

0 (0%)

0 (0%)

21 (7.8%)

80 (2.6%)

Smoking status

Current (%)

375 (15.7%)

91 (27.0%)

3 (4%)

8 (33%)

2 (13%)

52 (19.3%)

531 (17.0%)

Former (%)

1420 (59.3%)

214 (63.5%)

36 (49%)

12 (50%)

11 (74%)

170 (63.0%)

1863 (59.8%)

Never (%)

600 (25.0%)

32 (9.4%)

35 (48%)

4 (16%)

2 (13%)

48 (17.8%)

721 (23.1%)

Targetable alterations

EGFR^{L858R/exon19del/exon20ins} (%)

429 (17.9%)

3 (0.9%)

0 (0%)

0 (0%)

3 (20%)

20 (7.4%)

455 (14.6%)

KRAS^G12C (%)

367 (15.3%)

7 (2.1%)

0 (0%)

3 (12%)

0 (0%)

28 (10.4%)

405 (13.0%)

MET ^{amp/exon14skipping} (%)

108 (4.5%)

5 (1.5%)

0 (0%)

1 (4%)

2 (13%)

12 (4.4%)

128 (4.1%)

BRAF^V600E (%)

51 (2.1%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

5 (1.9%)

56 (1.8%)

ALK fusion (%)

61 (2.5%)

3 (0.9%)

0 (0%)

0 (0%)

0 (0%)

8 (3.0%)

72 (2.3%)

ROS1 fusion (%)

27 (1.1%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

4 (1.5%)

31 (1%)

RET fusion (%)

35 (1.5%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

2 (0.7%)

37 (1.2%)

NTRK fusion (%)

3 (0.1%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

1 (0.4%)

4 (0.1%)

Total

N (% of total samples)

2395 (76.9%)

337 (10.8%)

74 (2.4%)

24 (0.8%)

15 (0.5%)

270 (8.6%)

3115